Abstract
Although recombinant human erythropoietin (rhEpo) has been shown to be neuroprotective in experimental and clinical studies,1,2 prophylactic early high-dose rhEpo did not improve neurodevelopment among 2-year-olds who had been born very preterm in a randomized clinical trial.3 We report the prespecified secondary neurodevelopmental outcomes of the trial cohort at early school age.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
